Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ECOG Score of 0-1”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Testing effectiveness (Phase 2)Looking for participantsNCT07104149
What this trial is testing

Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer

Who this might be right for
Female, Age ≥ 18 Years OldNo Previous Systemic Treatment for the Current Disease, Including Surgery, Antitumor Radiochemotherapy/ImmunotherapyECOG Score of 0-1+6 more
The First Affiliated Hospital of Zhengzhou University 29
Not applicableEnded earlyNCT01073436
What this trial is testing

Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha

Who this might be right for
Chronic Myeloid Leukemia
University of Michigan Rogel Cancer Center 7
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06554535
What this trial is testing

Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer

Who this might be right for
Extensive-Stage Small Cell Lung CancerTreatment-naïve for Systemic Therapy Targeting Extensive-Stage Small Cell Lung CancerECOG Performance Status Score of 0 or 1+1 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Testing effectiveness (Phase 2)UnknownNCT05050630
What this trial is testing

Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL

Who this might be right for
Age Range ≥16 Years, Gender UnlimitedHistopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell LymphomaReceived Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed+4 more
Affiliated Hospital to Academy of Military Medical Sciences
43
73